Some agencies pride themselves on the originality of their thought and creativity. But we’ve taken originality one step further. We’ve actually had a patent granted.
We’re delighted to announce that Intimis, our marketing automation technology, has been granted a UK patent, and has more patents pending in several other key territories. The patent covers the technology which enables Intimis to offer their clients marketing automation, personalisation and behavioural tracking/retargeting without the need for software installation or cookies. This is a unique approach in the market and provides a secure, efficient and cost effective means of delivering these modern marketing techniques. Intimis has been developed with the support of the Creative Industries iNet.
Roger, our proud MD, said: “This patent is a great endorsement for our unique technology and stands as testament to the faith and hard work that so many people have put into it. At Proctors we firmly believe marketing automation will become more and more prevalent in the UK market. It has become a standard technology in the US. This country is just behind that curve but this will change once businesses recognise how much more economically their campaigns can be run.”
The efficiencies presented by implementing Intimis into clients’ marketing campaigns have shown clear benefits; one Proctor and Stevenson customer has seen a 260% increase in leads and another 50% reduction in cost-per-lead.
Kevin Mason, Head of Technology and Strategy at Proctor and Stevenson, commented: “It may seem somewhat unusual for a design and marketing communications company to invest in its own new technology, however the figures speak for themselves. The emerging marketing automation sector has been valued at $100 million and this is just the beginning. Equally, we see increasing convergence of media channels so it is becoming possible to offer much more precise metrics, our clients recognise this and those agencies that cannot meet their needs will be at a major disadvantage.”
For more information on Intimis, see www.intimis.com